Dr. Isaac Cann from the University of Illinois has identified biomarkers and therapeutic strategy for treatment of idiopathic pulmonary fibrosis (IPF) and lung cancer. This strategy has the potential to dramatically improve the lives of millions patients throughout the world. It is the first know effective treatment route for
IPF. The therapeutic strategy is based on the discovery of link between microbial community remodeling and IPF. Furthermore, the lung microbial community
can induce excessive apoptosis of alveolar lining epithelial cells leading to lung carcinogenesis.
Benefit
• Treatment strategies including broad spectrum antibiotics may be effective for treating IPF and preventing lung cancer